IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company’s lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
Metrics to compare | IOBT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIOBTPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.7x | −1.9x | −0.5x | |
PEG Ratio | −0.02 | −0.01 | 0.00 | |
Price/Book | 1.3x | 1.8x | 2.6x | |
Price / LTM Sales | - | 12.0x | 2.9x | |
Upside (Analyst Target) | - | 316.7% | 60.5% | |
Fair Value Upside | Unlock | 4.3% | 8.5% | Unlock |